KMM Group Takes RS2 Investment to Scale MedTech Manufacturing

KMM Group announced on July 27, 2026 that it completed an investment from RS2 Healthcare Partners, the Boston private equity firm formerly known as Riverside Partners. Neither the company nor the investor disclosed the amount, ownership stake, valuation, or transaction structure, so this is not a story about assigning a dramatic number to a blank space. It is a story about what KMM and RS2 are building around the capital.

The transaction announcement also appoints J. Mark King as President and CEO, moves co-founder John Shegda into the CTO role, and names co-founder Eric Wilhelm EVP of Business Transformation and Organizational Capability. That division of responsibilities matters because KMM does not sell a lightweight product that scales by adding a larger sales budget. It manufactures complex, tight-tolerance components for medical devices and other high-stakes industries, where process knowledge, quality systems, and production discipline are the product behind the product.

What Happened

RS2's investment gives KMM a healthcare-focused private equity partner at the same time the company is restructuring its leadership team for growth. King brings more than 30 years of medical device experience, including previous CEO roles at Tegra Medical and Clinical Innovations. Tegra was an RS2 portfolio company before its 2016 sale, giving King an established operating relationship with the investor now backing KMM.

Shegda and Wilhelm are not stepping into ceremonial founder roles. Shegda will lead engineering and technology strategy as CTO, while Wilhelm will focus on operational excellence and scalable growth in his transformation role. The arrangement keeps KMM's founders close to the technical and organizational systems they built while giving King responsibility for leading the company's next stage of expansion.

The deal should be described carefully. RS2 is a lower-middle-market healthcare investor, but neither company disclosed whether the transaction is a majority investment, minority position, control acquisition, or growth equity investment. RS2 reports $1.6B in capital commitments raised since 1989, but that reflects the firm's history rather than the size of its investment in KMM.

Why KMM Is an Attractive Manufacturing Platform

KMM was formed in 2020 through the combination of KVI Inc., M&S Centerless Grinding, and Meron Medical. The company itself is six years old, but the combined businesses contribute more than a century of manufacturing experience across machining, grinding, EDM, engineering, and assembly. That distinction matters because legacy experience demonstrates technical depth without overstating the age of the current organization.

The operating platform is unusually integrated for a specialized manufacturer. KMM combines CNC machining, centerless and cylindrical grinding, guidewire and corewire grinding, wire and ram EDM, design-for-manufacturability support, assembly, and managed secondary processes. Its 100,000-square-foot Hatboro facility was designed to consolidate those disciplines with R&D space, automation, quality control, and an ISO Class 8 cleanroom.

KMM also reports on-time delivery exceeding 99% and quality performance above 99.7%. Those are company-reported metrics rather than independently audited figures, but they describe the commercial promise RS2 is backing: difficult components manufactured consistently, documented properly, and moved from development into production without turning every handoff into a new source of risk.

Why MedTech Manufacturing Makes the Timing Important

Medical device OEMs do not outsource complexity simply to simplify procurement. They rely on specialized manufacturers because tight tolerances, difficult materials, regulated processes, and production scale require expertise and equipment that are impractical to replicate inside every device company. KMM's materials describe work across orthopedics, cardiovascular devices, guidewires, hypotubing, implants, delivery systems, and other applications where manufacturing reliability has direct clinical and commercial consequences. DevCuration's coverage of GT Medical Technologies moving toward commercial scale and Rejoni preparing for potential market entry illustrates the product-company side of the same manufacturing challenge.

The regulatory backdrop also shifted in 2026. The FDA's Quality Management System Regulation took effect on February 2 and incorporated ISO 13485:2016 into the federal medical device quality framework. KMM's single-site ISO 13485:2016 certificate covers contract manufacturing of instruments and components for orthopedic and cardiovascular applications.

That does not prove the regulatory change caused RS2 to invest, and neither company makes that claim. It does, however, make the strategic logic easier to understand. A manufacturer with integrated capabilities, a regulated quality system, and room to scale becomes more valuable when customers face greater expectations around supplier controls, documentation, and manufacturing discipline.

What the Leadership Design Signals

Private equity investments in founder-led manufacturers often create the same tension: the business needs more operational structure, but that structure cannot suffocate the judgment that wins technically demanding work. KMM's answer is to distribute leadership rather than assume one executive can simultaneously drive growth, engineering, technology, culture, and operational scale.

King brings the operating experience and investor relationship to lead the next phase. Shegda remains responsible for the manufacturing technology that differentiates KMM, while Wilhelm focuses on turning growth into repeatable operations. That is not a guarantee of success, but it is a coherent structure for scaling a business whose advantage lives inside machines, engineering decisions, operating procedures, and people who know when a drawing is about to become a production problem.

The company has not disclosed a specific use-of-proceeds plan. There is no announced equipment budget, hiring target, acquisition strategy, geographic expansion plan, or revenue goal. The responsible reading is narrower: RS2 is providing capital and healthcare manufacturing expertise while KMM aligns its leadership around engineering, operational excellence, and scalable growth.

What This Signals for the Market

The KMM transaction is another reminder that MedTech innovation depends on a manufacturing layer that rarely receives the headline. Devices can earn clinical interest and regulatory clearance, but commercialization still requires suppliers capable of managing materials, tolerances, process validation, traceability, and production volume without treating quality as an end-of-line inspection exercise.

RS2's investment is therefore less a bet on a single device category than on the infrastructure supporting many device programs. KMM also serves precision markets including aerospace, defense, space exploration, and high-tech manufacturing, but MedTech remains central to the investor's stated strategy. The opportunity is to expand a specialized manufacturing platform without diluting the technical depth that made it investable.

The capital matters. The leadership architecture may matter even more. KMM now has a healthcare-focused investor, a MedTech operating veteran in the CEO role, a founder leading technology, and a founder leading organizational transformation. The next measure of the partnership will not be the undisclosed investment amount. It will be whether KMM can expand capacity and complexity while making precision look repeatable rather than miraculous.